Drug · DIN 02553279
CRESEMBA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since May 12, 2025; first marketed May 12, 2025.
- Drug Identification Number (DIN)
- 02553279
- Company (DIN owner)
- Avir Pharma IncBlainville, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Isavuconazole J02AC05
- Class
- Human
- Record last updated
- July 24, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ISAVUCONAZOLE (ISAVUCONAZONIUM SULFATE) | 40 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- November 15, 2024: NOC 34383Supplement to a New Drug Submission (SNDS) · Addition of new pediatric indication: CRESEMBA (isavuconazole, as isavuconazonium sulfate) is an azole antifungal indicated for use in adults and pediatrics from 1 year to up to 18 years for the treatment of invasive aspergillosis and invasive mucormycosis. Addition of new strength: 40 mg capsule
Other DINs named CRESEMBA
- DIN 02483971 · Marketed
- DIN 02483998 · Marketed